BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast ...

BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites. "The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investi ...

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C., June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology po ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Laboratory Corporation of America Holdings or Labcorp (LH) recently introduced a screening test for preeclampsia in the first trimester, which will be done between weeks 11 and 14 of pregnancy to estimate the risk of preeclampsia before 34 weeks of pregnancy. This is the only test of its kind accessible in the United States and applicable to all expectant mothers, even those with first-time pregnancies or those at low to average risk of preeclampsia. With the latest launch, LK is now the only laboratory tha ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is well-poised to grow in the coming quarters, led by collaborations with leading pharmaceutical and biotechnology companies.  Labcorp also remains active on the acquisition front, maintaining a solid business development pipeline.However, adverse currency fluctuations are a concerning for the company.   In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% compared with a 4.7% rise of the industry and a 27.8% increase of the S&P 500 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 1-11353 LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) | Delaware | | 13-37573 ...

Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C., April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene thera ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.68 in the first quarter of 2024, up 6.4% from the year-ago quarter’s figure.The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 6.4%.On a GAAP basis, EPS in the first quarter was $2.69, up 12.6% from the last year’s comparable period.RevenuesRevenues in the quarter under review ro ...

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.com Kimbrel Arculeo (media) – 336-436-8263 Media@Labcorp.com Labcorp Announces 2024 First Quarter Results Updates Full-Year Guidance BURLINGTON, N.C., April 25, 2024 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2024 and updated full-year guidance. "Labcorp's first quarter performance sets a strong foundation ...